XML 36 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Note 17 - Related Party Transactions
 6 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]
17.
Related Party Transactions
 
Tris Pharma, Inc.
 
On
November 2, 2018,
the Company entered into a License, Development, Manufacturing and Supply Agreement (the “Tris License Agreement”). On
November 1, 2019,
the Company acquired the rights to Karbinal as a result of the acquisition of the Pediatric Portfolio from Cerecor, Inc. (See Notes
2
and
10
). Mr. Ketan Mehta serves as a Director on the Board of Directors of the Company and is also the Chief Executive Officer of TRIS. The Company paid TRIS approximately
$1.9
million and
$0.2
million
 during the
three
months ended
December 31, 2020
and
2019
, respectively for a combination of royalty payments, inventory purchases and other payments as contractually required. The Company's liabilities, including accrued royalties, contingent consideration and fixed payment obligations were
$24.1
 million and
$24.8
 million as of
December 31, 2020
and
2019
, respectively. I
n
October 2020,
the Company paid Tris approximately
$1.6
million related to its Karbinal fixed payment obligation.